Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease

Cited by (428)

Items 101–200 of 428

1. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease
   Stephen Burgess, Eric L. Harshfield · 2016 · Current Opinion in Endocrinology Diabetes and Obesity
2. Contribution of Gene Regulatory Networks to Heritability of Coronary Artery Disease
   Lingyao Zeng, Husain Ahammad Talukdar, Simon Koplev, Chiara Giannarelli, Torbjörn Ivert, Li‐Ming Gan, Arno Ruusalepp, Eric E. Schadt, Jason Ciril Kovacic, Aldons Jake Lusis et al. · 2019 · Journal of the American College of Cardiology
3. Plant sterol enriched functional food and atherosclerosis
   Jürgen Köhler, Daniel Teupser, Albrecht Elsässer, Oliver Weingärtner · 2017 · British Journal of Pharmacology
4. Loss-of-function variants influence the human serum metabolome
   Bing Yu, Alexander H. Li, Ginger Metcalf, Donna Marie Muzny, Alanna C. Morrison, Simon J. White, Thomas H. Mosley, Richard A. Gibbs, Eric Boerwinkle · 2016 · Science Advances
5. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
   Hayato Tada, Masayuki Takamura, Masa‐aki Kawashiri · 2019 · Journal of Atherosclerosis and Thrombosis
6. Personalized medicine for cardiovascular diseases
   Hayato Tada, Noboru Fujino, Akihiro Nomura, Chiaki Nakanishi, Kenshi Hayashi, Masayuki Takamura, Masa‐aki Kawashiri · 2020 · Journal of Human Genetics
7. Does Dietary Cholesterol Matter?
   Scott M. Grundy · 2016 · Current Atherosclerosis Reports
8. The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development
   Joshua C. Denny, Sara L. Van Driest, Wei‐Qi Wei, Dan M. Roden · 2017 · Clinical Pharmacology & Therapeutics
9. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)
   Makhmudova, Umidakhon, Samadifar, Beasat, Maloku, Aurel, Haxhikadrija, Pellumb, Geiling, Jens-Arndt, Römer, Robert, Lauer, Bernward, Möbius-Winkler, Sven, Otto, Sylvia, Schulze, P. Christian et al. · 2023 · Clinical Research in Cardiology
10. The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling
    Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se‐Hyung Park, Xiangping Zhou, Changcheng Zhou · 2019 · JCI Insight
11. Human genetics and its impact on cardiovascular disease
    Hayato Tada, Noboru Fujino, Kenshi Hayashi, Masa‐aki Kawashiri, Masayuki Takamura · 2021 · Journal of Cardiology
12. High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Piia P. Simonen, Katariina Öörni, Juha P. Sinisalo, Timo E. Strandberg, Ingmar Wester, Helena Gylling · 2023 · Atherosclerosis
13. Pathway and network-based strategies to translate genetic discoveries into effective therapies
    Casey S. Greene, Benjamin F. Voight · 2016 · Human Molecular Genetics
14. A Newly Integrated Model for Intestinal Cholesterol Absorption and Efflux Reappraises How Plant Sterol Intake Reduces Circulating Cholesterol Levels
    Takanari Nakano, Ikuo Inoue, Takayuki Murakoshi · 2019 · Nutrients
15. Effects of Dicyclohexyl Phthalate Exposure on PXR Activation and Lipid Homeostasis in Mice
    Yipeng Sui, Zhaojie Meng, Jianzhong Chen, Jingwei Liu, Rebecca Hernandez, Miko B. Gonzales, Taesik Gwag, Andrew J. Morris, Changcheng Zhou · 2021 · Environmental Health Perspectives
16. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials
    Abolfazl Doostparast Torshizi, Kai Wang · 2018 · Drug Discovery Today
17. Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches
    Teemu Niiranen, Ramachandran Srini Vasan · 2016 · Expert Review of Cardiovascular Therapy
18. Transcriptome-wide association study of coronary artery disease identifies novel susceptibility genes
    Ling Li, Zhifen Chen, Moritz von Scheidt, Shuangyue Li, Andrea Steiner, Ulrich Güldener, Simon Koplev, Angela Ma, Ke Hao, Calvin Pan et al. · 2022 · Basic Research in Cardiology
19. Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans
    Xie, Baocai, Shi, Xiaochen, Li, Yan, Xia, Bo, Zhou, Jia, Du, Minjie, Xing, Xiangyang, Bai, Liang, Liu, Enqi, Alvarez, Fernando et al. · 2021 · PLOS Genetics
20. Automating and improving cardiovascular disease prediction using Machine learning and EMR data features from a regional healthcare system
    Qi Li, Alina Câmpan, Ai Ren, Wael Eid · 2022 · International Journal of Medical Informatics
21. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases
    Pirillo, A., L. Catapano, A., D. Norata, G. · 2016 · Current Medicinal Chemistry
22. Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants
    Haiming Wang, Zifan Liu, Junjie Shao, Min Jiang, Xue-Chun Lu, Lejian Lin, Lin Wang, Qiang Xu, Haomin Stanley Zhang, Xin Li et al. · 2020 · Genes & Diseases
23. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials
    Ip, Chi-kin, Jin, Dong-mei, Gao, Jia-jia, Meng, Zhe, Meng, Jing, Tan, Zhi, Wang, Jing-feng, Geng, Deng-feng · 2015 · International Journal of Cardiology
24. The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
    Jaana Hartiala, William S. Schwartzman, Julian Gabbay, Anatole Ghazalpour, Brian J. Bennett, Hooman Allayee · 2017 · Current Atherosclerosis Reports
25. Developing Medicines That Mimic the Natural Successes of the Human Genome
    Sekar Kathiresan · 2015 · Journal of the American College of Cardiology
26. Rare Loss-of-Function Variants in NPC1 Predispose to Human Obesity
    Ruixin Liu, Yaoyu Zou, Jie Hong, Min Cao, Bin Cui, Huiwen Zhang, Maopei Chen, Juan Shi, Tinglu Ning, Shaoqian Zhao et al. · 2017 · Diabetes
27. Genotype-based clinical trials in cardiovascular disease
    Naveen L. Pereira, Daniel J. Sargent, Michael E. Farkouh, Charanjit S. Rihal · 2015 · Nature Reviews Cardiology
28. Intestinal Pregnane X Receptor Links Xenobiotic Exposure and Hypercholesterolemia
    Yipeng Sui, Robert Nathaniel Helsley, Se‐Hyung Park, Xiulong Song, Zun Liu, Changcheng Zhou · 2015 · Molecular Endocrinology
29. Network medicine in Cardiovascular Research
    Laurel Yong-Hwa Lee, Arvind Kant Pandey, Bradley A. Maron, Joseph Loscalzo · 2020 · Cardiovascular Research
30. The emerging concept of “individualized cholesterol-lowering therapy”: A change in paradigm
    Dieter Lütjohann, Frans Stellaard, Monique T Mulder, Eric J.G. Sijbrands, Oliver Weingärtner · 2019 · Pharmacology & Therapeutics
31. Sex Differences in Familial Hypercholesterolemia
    Marianne Klevmoen, Janneke W.C.M. Mulder, Jeanine E. Roeters van Lennep, Kirsten Bjørklund Holven · 2023 · Current Atherosclerosis Reports
32. Biomarkers of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718 patients
    Thomas D. Dayspring, Stephen A. Varvel, Leila Ghaedi, Dawn L. Thiselton, J. Lewis Bruton, Joseph P. McConnell · 2015 · Journal of clinical lipidology
33. Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
    Kirsten Bjørklund Holven, Ingunn Narverud, Jeanine E. Roeters van Lennep, Jorie Versmissen, Linn K. L. Øyri, Annette M.H. Galema‐Boers, Gisle Langslet, Stine Marie Ulven, Marit Bragelien Veierød, Kjetil Retterstøl et al. · 2018 · Journal of clinical lipidology
34. Opportunities and Challenges in Cardiovascular Pharmacogenomics
    Dan M. Roden, Sara L. Van Driest, Quinn Stanton Wells, Jonathan D. Mosley, Joshua C. Denny, Josh F. Peterson · 2018 · Circulation Research
35. A consensus statement on lipid management after acute coronary syndrome
    François Schiele, Michel Farnier, Michel Krempf, Éric Bruckert, Jean Ferrières, Denis Angoulvant, Franck Boccara, Jacques Bonnet, Jean‐Louis Bonnet, Eric Bruckert et al. · 2016 · European Heart Journal Acute Cardiovascular Care
36. Association of Dietary Phytosterols with Cardiovascular Disease Biomarkers in Humans
    Ramandeep Kaur, Semone B. Myrie · 2020 · Lipids
37. Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices
    Pradeep Natarajan, Akhil Pampana, Sarah E. Graham, Sanni Ruotsalainen, James A. Perry, Paul S. de Vries, Jai Broome, James P. Pirruccello, Michael C. Honigberg, Krishna G. Aragam et al. · 2021 · Nature Communications
38. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia
    Kristin Torvik, Ingunn Narverud, Inger Olaug Ottestad, Arne Svilaas, Jon Michael Gran, Kjetil Retterstøl, Asta Ellingvåg, Ellen Strøm, Leiv Ose, Marit Bragelien Veierød et al. · 2016 · Atherosclerosis
39. Genetically modulated educational attainment and coronary disease risk
    Lingyao Zeng, Ιωάννα Ντάλλα, Thorsten Kessler, Adnan Kastrati, Jeanette Erdmann, John Danesh, Hugh C Watkins, Nilesh J. Samani, Panos Deloukas, Heribert Schunkert · 2019 · European Heart Journal
40. Lipids in South Asians: Epidemiology and Management
    Minhal Makshood, Wendy S. Post, Alka M. Kanaya · 2019 · Current Cardiovascular Risk Reports
41. Recent advances in the pharmacological management of hypercholesterolaemia
    Ezim Ajufo, Daniel James Rader · 2016 · The Lancet Diabetes & Endocrinology
42. Ezetimibe plus a Statin after Acute Coronary Syndromes
    Günther Silbernagel, Baumgartner, Iris, März, Winfried · 2015 · New England Journal of Medicine
43. Human Genomics and Drug Development
    Amand Floriaan Schmidt, Aroon Dinesh Hingorani, Chris Finan · 2021 · Cold Spring Harbor Perspectives in Medicine
44. Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention
    Marju Orho‐Melander · 2015 · Journal of Internal Medicine
45. Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles
    John Gregson, Daniel F. Freitag, Praveen Surendran, Nathan O. Stitziel, Rajiv Chowdhury, Stephen Burgess, Stephen K. Kaptoge, Pei Gao, James R Staley, Peter Willeit et al. · 2016 · European Journal of Preventive Cardiology
46. Establishing the precise evolutionary history of a gene improves prediction of disease-causing missense mutations
    Ogün Adebalı, Alexander O. Reznik, Daniel S. Ory, Igor B. Zhulin · 2016 · Genetics in Medicine
47. Meta-analysis of 49 549 individuals imputed with the 1000 Genomes Project reveals an exonic damaging variant in ANGPTL4 determining fasting TG levels
    Elisabeth M van Leeuwen, Aniko Sabo, Joshua C. Bis, Jennifer E. Huffman, Ani W Manichaikul, Albert V. Smith, Mary Furlan Feitosa, Serkalem Demissie, Peter K. Joshi, Qing Duan et al. · 2016 · Journal of Medical Genetics
48. Novel functions of PXR in cardiometabolic disease
    Changcheng Zhou · 2016 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
49. Increased plant sterol deposition in vascular tissue characterizes patients with severe aortic stenosis and concomitant coronary artery disease
    Alexandra Luister, Hans-Frieder Schött, Constanze Husche, Hans‐Joachim Schäfers, Michael Böhm, Jogchum Plat, Stefan Gräber, Dieter Lütjohann, Ulrich Laufs, Oliver Weingärtner · 2015 · Steroids
50. Optimal sequencing strategies for identifying disease-associated singletons
    Sara R. Rashkin, Goo Jun, Sai Chen, Gonçalo R. Abecasis · 2017 · PLoS Genetics
51. Effects of Phytosterol Supplementation on Serum Levels of Lipid Profiles, Liver Enzymes, Inflammatory Markers, Adiponectin, and Leptin in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
    Majid Mohammad Shahi, Mohammad Ali Javanmardi, Seyed Saeed Seyedian, Mohammad Hosein Haghighizadeh · 2018 · Journal of the American College of Nutrition
52. GWAS as a Driver of Gene Discovery in Cardiometabolic Diseases
    Biljana Atanasovska, Vinod Kumar, Jingyuan Fu, Cisca Wijmenga, Marten H. Hofker · 2015 · Trends in Endocrinology and Metabolism
53. Cis -epistasis at the LPA locus and risk of cardiovascular diseases
    Lingyao Zeng, Sylvain Moser, Nazanin Mirza‐Schreiber, Claudia Lamina, Stefan Coassin, Christopher P. Nelson, Tarmo Annilo, Oscar Franzén, Marcus Edi Kleber, Salome Rebecca Mack et al. · 2021 · Cardiovascular Research
54. Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia
    António Miguel Ferreira, Pedro Marques da Silva · 2016 · American Journal of Cardiovascular Drugs
55. A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol1
    Fuentes, Mari C., Lajo, Teresa, Carrión, Juan M., Cuñé, Jordi · 2016 · Mediterranean Journal of Nutrition and Metabolism
56. Dietary fat quality, plasma atherogenic lipoproteins, and atherosclerotic cardiovascular disease: An overview of the rationale for dietary recommendations for fat intake
    Jacob Juel Christensen, Erik Arnesen, Amanda Rundblad, Vibeke H. Telle‐Hansen, Ingunn Narverud, Rune Blomhoff, Martin Prøven Bogsrud, Kjetil Retterstøl, Stine Marie Ulven, Kirsten Bjørklund Holven · 2023 · Atherosclerosis
57. Integrating electronic health record genotype and phenotype datasets to transform patient care
    Dan M. Roden, Joshua C. Denny · 2015 · Clinical Pharmacology & Therapeutics
58. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
    Kiran Musunuru · 2020 · Annual Review of Medicine
59. Cardiovascular pharmacogenomics: current status and future directions
    Dan M. Roden · 2015 · Journal of Human Genetics
60. Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease
    Le Shu, Montgomery Blencowe, Xia Yang · 2018 · Frontiers in Cardiovascular Medicine
61. IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease
    Alberico Luigi Catapano, Brian A. Ference · 2015 · Atherosclerosis
62. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
    Umidakhon Makhmudova, Elisabeth Steinhagen‐Thiessen, Massimo Volpe, Ulf Landmesser · 2024 · Cardiovascular Research
63. Leveraging human genetics to guide drug target discovery
    Nathan O. Stitziel, Sekar Kathiresan · 2016 · Trends in Cardiovascular Medicine
64. Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
    Qin Hu, Panpan Hao, Qiji Liu, Mei Dong, Yaoqin Gong, Cheng Zhang, Yun Zhang · 2019 · Science China Life Sciences
65. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease
    Jacqueline S. Dron, Aniruddh P. Patel, Yiyi Zhang, Sean Joseph Jurgens, Dimitri J. Maamari, Minxian Wang, Eric Boerwinkle, Alanna C. Morrison, Paul S. de Vries, Myriam Fornage et al. · 2023 · JAMA Cardiology
66. The Role of Statins in Current Guidelines
    Fabiana Hanna Rached, Raul Dias Santos · 2020 · Current Atherosclerosis Reports
67. The Future of Cardiovascular Therapeutics
    Calum A. MacRae, Dan M. Roden, Joseph Loscalzo · 2016 · Circulation
68. Special Commentary
    Samuel S. Gidding · 2018 · Current Opinion in Clinical Nutrition & Metabolic Care
69. Mendelian randomization: Its impact on cardiovascular disease
    Masa‐aki Kawashiri, Hayato Tada, Akihiro Nomura, Masakazu Yamagishi · 2018 · Journal of Cardiology
70. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene
    Hayato Tada, Hirofumi Okada, Akihiro Nomura, Masayuki Takamura, Masa‐aki Kawashiri · 2020 · Lipids in Health and Disease
71. Increased genetic risk for obesity in premature coronary artery disease
    Christopher B Cole, Majid Nikpay, Alexandre F.R. Stewart, Ruth McPherson · 2015 · European Journal of Human Genetics
72. Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology
    Hayato Tada, Soichiro Usui, Kenji Sakata, Masayuki Takamura, Masa‐aki Kawashiri · 2020 · Journal of Atherosclerosis and Thrombosis
73. m6A-related bioinformatics analysis and functional characterization reveals that METTL3-mediated NPC1L1 mRNA hypermethylation facilitates progression of atherosclerosis via inactivation of the MAPK pathway
    Guoan Zhang, Xuewen Li, Xiaoyan Huang · 2022 · Inflammation Research
74. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
    RICHARD J. KONES, Umme Rumana · 2015 · Drugs
75. Current pharmacotherapeutic options for primary dyslipidemia in adults
    Arrigo F.G. Cicero, Matteo Landolfo, Fulvio Ventura, Claudio Borghi · 2019 · Expert Opinion on Pharmacotherapy
76. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition
    Jessica Mwinyi, Adrian E. Desai Boström, Claudia Pisanu, Susan K. Murphy, Wiebke Erhart, Clemens Schafmayer, Jochen Hampe, Cynthia A. Moylan, Helgi B. Schiöth · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
77. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
    Christie Mitchell Ballantyne, Giuseppe Danilo Norata · 2025 · European Heart Journal
78. The Inherited Basis of Coronary Artery Disease
    Heribert Schunkert, Pradeep Natarajan, Nilesh J. Samani · 2026 · New England Journal of Medicine
79. Potential use of the cholesterol transfer inhibitor U18666A as an antiviral drug for research on various viral infections
    Marjan Assefi, Reza Bijan Rostami, Menooa Ebrahimi, Mana Altafi, Pooya M. Tehrany, Haider Kamil Zaidan, Bashar Zuhair Talib Al-Naqeeb, Meead Hadi, Saman Yasamineh, Omid Gholizadeh · 2023 · Microbial Pathogenesis
80. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia
    Ya-Bin Ma, Paul Chan, Yuzhen Zhang, Brian Tomlinson, Zhongmin Liu · 2019 · Expert Opinion on Pharmacotherapy
81. Causal Inference Methods to Integrate Omics and Complex Traits
    Eleonora Porcu, Jennifer Sjaarda, Kaido Lepik, Cristian Carmeli, Liza Darrous, Jonathan Sulc, Ninon Mounier, Zoltán Kutalik · 2020 · Cold Spring Harbor Perspectives in Medicine
82. Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis
    Maciej Banach, Vikash Jaiswal, Song Peng Ang, Aanchal Sawhney, Novonil Deb, Pierre Amarenco, Dan Ion Gaiță, Željko Reiner, Ivan Pećin, Carl J. Lavie et al. · 2025 · Mayo Clinic Proceedings
83. Dietary sinapic acid attenuated high‐fat diet‐induced lipid metabolism and oxidative stress in male Syrian hamsters
    Keying Wang, Chanhua Liang, Wenjing Cao, Gao Luo, Shumei Zhong, Zhen Zeng, Ling Dai, Jia‐Le Song · 2022 · Journal of Food Biochemistry
84. Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
    Veronika Sanin, Vanessa Pfetsch, Wolfgang Köenig · 2017 · Current Cardiology Reports
85. Molecular analysis of APOB, SAR1B, ANGPTL3, and MTTP in patients with primary hypocholesterolemia in a clinical laboratory setting: Evidence supporting polygenicity in mutation-negative patients
    Francisco Blanco‐Vaca, Jesús María Martín-Campos, Ángel Beteta-Vicente, Marina Canyelles, Susana Martínez, Rosa Roig, Núria Farré, Josep Julve, Mireia Tondo · 2019 · Atherosclerosis
86. Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet–Induced Atherosclerosis in LDL Receptor Mutant Mice
    Hideaki Yamamoto, Yoshihide Yamanashi, Tappei Takada, Shuang Mu, Yusuke Tanaka, Toko Komine, Hiroshi Suzuki · 2019 · Molecular Pharmacology
87. Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins
    DeForest, Natalie, Kavitha, Babu, Hu, Siqi, Isaac, Roi, Krohn, Lynne, Wang, Minxian, Du, Xiaomi, De Arruda Saldanha, Camila, Gylys, Jenny, Merli, Edoardo et al. · 2023 · Cell Genomics
88. Ezetimibe plus simvastatin for the treatment of hypercholesterolemia
    Steven E. Gryn, Robert Alexander Hegele · 2015 · Expert Opinion on Pharmacotherapy
89. Genetic association studies in cardiovascular diseases: Do we have enough power?
    Paul Livermore Auer, Nathan O. Stitziel · 2017 · Trends in Cardiovascular Medicine
90. Disconnect Between Genes Associated With Ischemic Heart Disease and Targets of Ischemic Heart Disease Treatments
    Catherine Mary Schooling, Jian V. Huang, Jie V. Zhao, Man Ki Kwok, Shiu Lun Au Yeung, Shi Lin Lin · 2018 · EBioMedicine
91. Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases
    Benoît J. Arsenault, Nicolas Perrot, Rishi Puri · 2018 · Clinical Pharmacology & Therapeutics
92. Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk
    Vinicius Tragante, Folkert Wouter Asselbergs, Daniel I. Swerdlow, Tom Palmer, Jason H. Moore, Paul I. W. de Bakker, Brendan J. Keating, Michael Vaclav Holmes · 2016 · Human Genetics
93. LDL-Cholesterol: Standards of Treatment 2016: A German Perspective
    Winfried März, Hubert Scharnagl, Ioanna Gouni‐Berthold, Günther Silbernagel, Alexander Dressel, Tanja B. Grammer, Ulf Landmesser, Hans Dieplinger, Eberhard Windler, Ulrich Laufs · 2016 · American Journal of Cardiovascular Drugs
94. Personalized medicine in cardiovascular disease: review of literature
    Ali Sheikhy, Aida Fallahzadeh, Hamid Reza Aghaei Meybodi, Mandana Hasanzad, Masih Tajdini, Kaveh Hosseini · 2021 · Journal of Diabetes & Metabolic Disorders
95. Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
    Farzahna Mohamed, Brett Stephen Mansfield, Frederick Johan Raal · 2023 · Journal of Clinical Medicine
96. Recent advances in the management and implementation of care for familial hypercholesterolaemia
    Nick S.R. Lan, Archna Bajaj, Gerald Francis Watts, Marina Cuchel · 2023 · Pharmacological Research
97. Fisetin, a dietary flavonoid, promotes transintestinal cholesterol excretion through the activation of PPARδ
    Yao Guo, Bing Liu, Yaping Geng, Ke Chen, Junyan Li, Xiangju Yin, Shenshen Zhang · 2023 · Food Research International
98. IMPROVE-IT
    Maciej Banach, Dragana Nikolić, Manfredi Rizzo, Peter Paul Toth · 2016 · Current Opinion in Cardiology
99. Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations
    Philip G. Joseph, Guillaume Paré, Senay Asma, James C. Engert, Salim Yusuf, Sonia Savitri Anand · 2016 · Canadian Journal of Cardiology
100. LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?
     Raimund Weitgasser, Michaela Ratzinger, Margit Hemetsberger, Peter Siostrzonek · 2016 · Wiener Medizinische Wochenschrift